News

Patients with hereditary angioedema experience high adherence and persistence rates with berotralstat, lanadelumab, and SC-pdC1-INH for long-term prophylaxis.

XGBoost displayed a high rate of accuracy, sensitivity, and precision, indicating its effectiveness at highlighting depressive symptoms before diagnosis.

New findings reveal that higher HbA1c levels worsen asthma control in children, linking metabolic dysfunction to increased asthma morbidity.

EBX-102-02 was well tolerated and led to clinically meaningful improvements across multiple symptom domains in patients with IBS-C.

These data suggest that heart health, as determined by the LC9 assessment, is positively correlated with pulmonary health.

Subgroup analysis findings highlight duvakitug’s efficacy and tolerability across different levels of inflammation in ulcerative colitis.

Digital inhalers enhance asthma control and reduce severe exacerbations, offering promising benefits with minimal harm for patients struggling with adherence.

Biomarker-informed molecular guidance led to greater achievement of disease control compared with standard “best care” for IBD anti-TNF therapy.

Gregory Cote, MD, reviews SHARP trial data suggesting ERCP with miES does not reduce acute pancreatitis risk in acute recurrent pancreatitis and pancreas divisum.

Virtual pulmonary rehabilitation enhances access and improves outcomes for COPD patients, demonstrating safety and effectiveness in individualized care.

FDA approves 12.5 mg chlorthalidone tablets, enhancing hypertension treatment options and aligning with clinical guidelines for better patient outcomes.

Our April 2025 month in review highlights significant advancements in endocrinology, including innovative therapies and FDA approvals that enhance diabetes management.

New research reveals Medicaid unwinding disrupts chronic medication access for young adults, risking health and treatment outcomes amid enrollment losses.

This analysis highlighted the cardiovascular safety of systemic psoriasis drugs using a prospective cohort trial design.

A post hoc analysis of data from the PULSAR trial indicates that patients with aflibercept 8 mg achieved disease activity control early and in high proportion.

Anthony Kerbage, MD, explains the heightened risk of repeat screening colonoscopy among patients with a primary language other than English.

Our April 2025 month in review highlights breakthroughs in gene therapy, device innovations, and evolving treatment strategies for cardiology.

Mazen Noureddin, MD, MHSc, reviews findings from a phase 2 study of efimosfermin alfa (BOS-580) for F2/F3 fibrosis due to MASH.

These post-hoc analysis findings align with POETYK PSO-4 regarding deucravacitinib’s effectiveness in patients with psoriasis.

Findings from a posthoc analysis of 2 phase 3 trials suggest seladelpar monotherapy has similar safety and efficacy to seladelpar combined with UDCA.

AI enhances prediction, diagnosis, and treatment of allergic diseases including asthma, atopic dermatitis, and food allergies, offering personalized, efficient care.

UBX1325 exhibited noninferiority to aflibercept in difficult-to-treat diabetic macular edema, while maintaining a favorable safety profile in the ASPIRE study.

Fendrick describes patients’ desire for green screening options and reviews findings from a study comparing the environmental impact of screening tools.

This analysis suggests intake of riboflavin, also known as vitamin B2, shows an association with patients’ risk of developing psoriasis.

New research uncovers unique brain abnormalities linked to sleep disorders and deprivation, revealing insights into emotional and cognitive impacts.

New triple therapy BGF shows significant and clinically meaningful lung function improvement in patients with uncontrolled asthma, with full data readouts coming soon.

Zhang describes the importance of multidisciplinary care for preventing alcohol relapse post-transplant, citing success from Mass General’s LIFT Clinic.

Gold explains misconceptions about who is affected by EoE and describes the importance of understanding the impact of SDoH in this patient population.